Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
Pharmacol Rep. 2009 Nov-Dec;61(6):1173-8. doi: 10.1016/s1734-1140(09)70180-x.
The obtained results revealed that joint administration of desipramine or reboxetine and metyrapone (a glucocorticoid synthesis inhibitor) had more potent antidepressant-like activity in the forced swimming test (FST) in rats compared to treatment with either drug alone. WAY100636 (a 5-HT(1A) antagonist), and prazosin (an alpha(1)-adrenergic antagonist), used in doses ineffective in the FST, inhibited the antidepressant-like effect induced by co-administration of desipramine (10 mg/kg) or reboxetine (10 mg/kg) and metyrapone (50 mg/kg). The above-mentioned findings suggest that, among other mechanisms, the 5-HT(1A) and alpha(1)-adrenergic receptors may play a role in this effect. Furthermore, they may be of particular importance to the pharmacotherapy of drug-resistant depression.
所得结果表明,与单独使用任何一种药物相比,去甲丙咪嗪或瑞波西汀与米曲酮(一种糖皮质激素合成抑制剂)联合给药在大鼠强迫游泳试验(FST)中具有更强的抗抑郁样活性。WAY100636(5-HT1A 拮抗剂)和哌唑嗪(α1-肾上腺素能拮抗剂)以在 FST 中无效的剂量使用,可抑制去甲丙咪嗪(10mg/kg)或瑞波西汀(10mg/kg)与米曲酮(50mg/kg)联合给药引起的抗抑郁样作用。上述发现表明,除其他机制外,5-HT1A 和α1-肾上腺素能受体可能在这种作用中发挥作用。此外,它们可能对耐药性抑郁症的药物治疗特别重要。